Redox Homeostasis Modulators

Through a rational design programme, our team has identified key pharmacophores around a chemical class targeting the modulation of redox homeostasis. Experimental data show that these compounds are potent inducers of oxidative stress, perturb the cell cycle, induce apoptosis and inhibit HIF-1a signal transduction and the expression of VEGF. Anti-tumour activity has been demonstrated in xenograft models against a number of common solid tumours, including colon, breast, renal and pancreatic.

Our lead candidate, PMX 2058, is a water soluble pro-drug of the active moiety, PMX 290. It is scheduled to enter regulatory toxicology studies in the second half of 2009.

Our experimental data suggest that these compounds are able to modulate redox homeostasis in several ways and the wide-ranging anti-tumour activity of these compounds may be due to multiple mechanisms of action, including:

  • Print this page
  • Email this page to a friend

Relevant Publications

External Link Antitumour quinols: Role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets.
 
External Link Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study.
 
External Link Elucidation of thioredoxin as a molecular target for antitumour quinols.
 
External Link Induction and apoptosis without redox catastrophe by thioredoxin-inhibitory compounds.
 
External Link Novel thioredoxin inhibitors paradoxically increase Hypoxia-inducible factor-α expression but decrease functional transcriptional activity, DNA binding, and degradation.

Additional Bibliography
 
Diagrams
 
Download PDF Model of PMX 464 Bound to Human Thioredoxin
(1,600kb)